$GILD Company News 10 stocks loved by advisers who beat

New Post Public Reply Private Reply Replies (0) Message Board

Oct 21, 2014 at 12:30 PM

$GILD Company News

10 stocks loved by advisers who beat bear markets 7:35 p.m. Oct. 15, 2014 - Mark Hulbert
NYSE to expand number of companies on biotech index 5:52 p.m. Oct. 14, 2014 - Wallace Witkowski
J&J's earnings jump on higher drug sales 8:12 a.m. Oct. 14, 2014 - MarketWatch.com
Gilead’s new drug is even pricier than Sovaldi 5:29 p.m. Oct. 10, 2014 - Russ Britt
The most profitable companies get the best stock returns 8:31 a.m. Oct. 10, 2014 - Philip van Doorn
Bristol-Myers drops Hepatitis C dual regimen in U.S. 11:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
Mylan boosts full-year outlook on product launches 8:11 a.m. Oct. 3, 2014 - MarketWatch.com
During times like these, cash is king 2:03 p.m. Oct. 2, 2014 - The Trading Deck
Sovaldi pricing raises debate over drug costs 2:57 p.m. Oct. 1, 2014 - Jani Actman of Medill News Service
It’s crucial to watch growth stocks right now 3:06 p.m. Sept. 25, 2014 - The Trading Deck
Gilead Sciences shares up 1.5% 9:39 a.m. Sept. 25, 2014 - Sue Chang
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn
Market pullbacks present promise, not peril 1:58 p.m. Sept. 16, 2014 - The Trading Deck
Gilead Sciences shares slide 2.6% 9:39 a.m. Sept. 15, 2014 - Sue Chang
Two tech stocks with big potential 2:14 p.m. Sept. 11, 2014 - The Trading Deck
Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore

BI begins enrollment in Phase 3 CRC trial 9:08 a.m. Today - Seeking Alpha
Gilead Sciences: Clear The Dockets And Settle With Merck Already 9:07 a.m. Today - Seeking Alpha
Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings 5:01 p.m. Oct. 20, 2014 - Investors Business Daily
3 Drugs Stocks Pushing Industry Growth 1:17 p.m. Oct. 20, 2014 - TheStreet.com
Stocks Slide on Indiscriminate Selling 10:40 a.m. Oct. 20, 2014 - Barrons.com
LabCorp launches new HIV test 10:40 a.m. Oct. 20, 2014 - Seeking Alpha
Gilead: Stage Set For Rally 8:27 a.m. Oct. 20, 2014 - Seeking Alpha
End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies 7:40 a.m. Oct. 20, 2014 - Seeking Alpha
Cramer's Lightning Round - Ensco Is One Of The Worst Stocks I've Owned In My Life (10/17/14) 6:24 a.m. Oct. 19, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Lots of Ways to Win With Molson Coors 6:00 a.m. Oct. 18, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:16 p.m. Oct. 17, 2014 - TheStreet.com
Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog 4:30 p.m. Oct. 17, 2014 - Zacks.com
A Harvoni Vs. Olysio Price War Will Be Nonexistent: Consider Buying Gilead Now 1:54 p.m. Oct. 17, 2014 - Seeking Alpha
Health Canada issues notice of compliance for Gilead's Harvoni(TM) (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C 2:44 p.m. Oct. 16, 2014 - CNW Group
2 Companies That Don't Deserve This Market Beatdown 8:14 a.m. Oct. 16, 2014 - Seeking Alpha
Novavax Begins Mid-Stage Study on RSV Vaccine in Elders - Analyst Blog 5:20 p.m. Oct. 15, 2014 - Zacks.com
Best U.S. Stock Ideas Today 3:57 p.m. Oct. 15, 2014 - Seeking Alpha
Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark' 3:42 p.m. Oct. 15, 2014 - benzinga.com
Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog 1:59 p.m. Oct. 15, 2014 - Zacks.com
Healthcare ETFs in Focus on JNJ Earnings Beat - ETF News And Commentary 1:00 p.m. Oct. 15, 2014 - Zacks.com

Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Oct. 20, 2014 - PR Newswire - PRF
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:30 p.m. Oct. 16, 2014 - BusinessWire - BZX
Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver 9:31 a.m. Oct. 15, 2014 - PR Newswire - PRF
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma 9:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:54 p.m. Oct. 10, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher 8:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults 7:18 a.m. Sept. 26, 2014 - BusinessWire - BZX
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 10:33 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 9:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies 8:30 a.m. Sept. 24, 2014 - BusinessWire - BZX
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection 12:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo 9:05 a.m. Sept. 22, 2014 - PR Newswire - PRF
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 6:23 a.m. Sept. 19, 2014 - BusinessWire - BZX
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer 6:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
AHF Joins National Coalition on Health Care’s ‘Campaign for Sustainable Rx Pricing’ 6:21 p.m. Sept. 16, 2014 - BusinessWire - BZX
Hetero Enters License Agreement With Gilead Sciences Inc., USA to Produce Generic Sofosbuvir for Treatment of Chronic Hepatitis C 5:50 p.m. Sept. 16, 2014 - Marketwire
Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries 6:30 a.m. Sept. 15, 2014 - BusinessWire - BZX
Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries 6:30 a.m. Sept. 15, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Casio Unveils Analog G-SHOCKs with Iconic Style

Blending the Old with the New Here's an interesting tidbit for all you watch aficionados and investors: Casio is set to drop the GMC-2500 and GAC-2500, a new wave of G-SHOCK watches that are marrying that vintage cool with today's swagger. Straight out of Tokyo, these timepieces are taking a page from the 1983 DW-5000C playbook, but the twist? They're going analog. It's a...

Supermicro Unleashes Liquid-Cooled AI Masterpiece

The Shift to Liquid-Cooled AI With AI ramping up faster than a caffeinated day trader, it's no wonder Supermicro is getting into the liquid-cooled game with their swanky new NVIDIA Vera CPU rack—a real game-changer for clunky data centers. Built for today's over-the-top agentic AI, this rack isn't just some flashy new gizmo. It's 100% liquid-cooled and ready to handle...

Sony's Game-Changing Sensor Reshapes Medical Endoscopy

In a world where medical tech innovation can make the difference between life and death, Sony’s latest feat will turn some heads in the healthcare industry. This ain’t about another PlayStation release; we’re talking the IMX742 CMOS image sensor crafted for single-use endoscopes. As far as breakthroughs go, the microscopic square sensor packs a surprising punch by...

Littleton U-Pull-It Kicks off New Era with a Bang

A Fresh Chapter for Littleton U-Pull-It There's nothing quite like the thrill of a new beginning, especially when it promises to shake up the local business scene. Littleton U-Pull-It, under new ownership, seems to be gearing up for exactly that. They're setting the stage with a grand opening event on October 24. When old hands in the business world like me see moves like...

Chemours Faces Class Action: Fraud Allegations Unpacked

The Chemours Enigma: Class Action Lawsuit and Investor Reactions Ah, The Chemours Company, or as the market knows it, NYSE:CC. This time, they're not hitting headlines for some cutting-edge chemical marvel; instead, it's the ugly world of class actions and allegations of securities fraud lighting up their scene. Grab your coffee; this dicey drama kicks off with a class...

ManpowerGroup to Feature at J.P. Morgan Conference

ManpowerGroup Heads to the Big Apple ManpowerGroup's top brass are packing their bags for New York City, heading to the J.P. Morgan Ultimate Services Investor Conference. Now, this isn’t just another cookie-cutter investor meet-up. Jack McGinnis, the CFO, and Becky Frankiewicz, the President and Chief Strategy Officer, are slated to have a fireside chat on November 17,...

Unlock NYC's Best Corporate Holiday Party Venues 2026

Scouting NYC's Premier Party Spots Finding the right venue in New York City for a corporate holiday party isn't as simple as picking out the fanciest ballroom or chicest rooftop terrace. It's a game of seating layouts, cocktail capacities, and calendar slots that are tighter than a Wall Street squeeze. EMRG Media is dropping its 2026 Guide to NYC's best corporate holiday...

Vermiculus Unveils VeriIndex: A Game-Changer for Indices

Standing on the Precipice of Index Innovation There’s a seismic shift rumbling through Vermiculus as they roll out their latest brainchild, the VeriIndex. This isn’t just your typical release; it’s the kind of shakeup that slaps you awake like a splash of cold water. Ever since they burst onto the scene in 2020, Vermiculus has been stirring the pot of exchange...

Third Eye Demands Fairer Terms for SkyAI Buyout

Revamping the SkyAI Tender Offer Third Eye's backing of Bastion Trading's push for better terms in SkyAI's tender offer has put a spotlight on those crafty boardroom maneuvers. Investors aren't exactly thrilled with the crumbs being thrown their way, and it's about time someone held the cooks accountable. Getting What's Owed Here's the gist of it: Third Eye's not asking...

WF Holding Cancels Additional Purchase Rights in Deal

WF Holding Calls Off Extra Purchase Rights Well, someone's decided to hit the brakes over at WF Holding Limited (NASDAQ:WFF). They're pulling the plug on an extra purchase gravy train they’d previously left open for investors. Straight from Kuala Lumpur, WF Holding's been in the fiberglass plastic game for over three decades, pushing out a product line that's almost as...